Literature DB >> 23836875

Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.

Andreas Keller1, Petra Leidinger, Florian Steinmeyer, Cord Stähler, Andre Franke, Georg Hemmrich-Stanisak, Andreas Kappel, Ian Wright, Jan Dörr, Friedemann Paul, Ricarda Diem, Beatrice Tocariu-Krick, Benjamin Meder, Christina Backes, Eckart Meese, Klemens Ruprecht.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) are short, noncoding RNAs with gene regulatory functions whose expression profiles may serve as disease biomarkers.
OBJECTIVE: The objective of this study was to perform a comprehensive analysis of miRNA expression profiles in blood of patients with a clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) including next-generation sequencing (NGS).
METHODS: miRNA expression was analyzed in whole blood samples from treatment-naïve patients with CIS (n = 25) or RRMS (n = 25) and 50 healthy controls by NGS, microarray analysis, and quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: In patients with CIS/RRMS, NGS and microarray analysis identified 38 and eight significantly deregulated miRNAs, respectively. Three of these miRNAs were found to be significantly up- (hsa-miR-16-2-3p) or downregulated (hsa-miR-20a-5p, hsa-miR-7-1-3p) by both methods. Another five of the miRNAs significantly deregulated in the NGS screen showed the same direction of regulation in the microarray analysis. qRT-PCR confirmed the direction of regulation for all eight and was significant for three miRNAs.
CONCLUSIONS: This study identifies a set of miRNAs deregulated in CIS/RRMS and reconfirms the previously reported underexpression of hsa-miR-20a-5p in MS. hsa-miR-20a-5p and the other validated miRNAs may represent promising candidates for future evaluation as biomarkers for MS and could be of relevance in the pathophysiology of this disease.

Entities:  

Keywords:  Multiple sclerosis; biomarker; clinically isolated syndrome; microRNAs; microarray; next-generation sequencing; real-time polymerase chain reaction

Mesh:

Substances:

Year:  2013        PMID: 23836875     DOI: 10.1177/1352458513496343

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  58 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Deep characterization of blood cell miRNomes by NGS.

Authors:  Eva C Schwarz; Christina Backes; Arne Knörck; Nicole Ludwig; Petra Leidinger; Cora Hoxha; Gertrud Schwär; Thomas Grossmann; Sabine C Müller; Martin Hart; Jan Haas; Valentina Galata; Isabelle Müller; Tobias Fehlmann; Hermann Eichler; Andre Franke; Benjamin Meder; Eckart Meese; Markus Hoth; Andreas Keller
Journal:  Cell Mol Life Sci       Date:  2016-02-13       Impact factor: 9.261

3.  Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.

Authors:  Jaspreet Singh; Mandar Deshpande; Hamid Suhail; Ramandeep Rattan; Shailendra Giri
Journal:  J Neuroimmune Pharmacol       Date:  2015-08-16       Impact factor: 4.147

Review 4.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 5.  Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.

Authors:  Vaibhav Singh; Ajai Tripathi; Ranjan Dutta
Journal:  Proteomics       Date:  2019-06-21       Impact factor: 3.984

6.  The deterministic role of 5-mers in microRNA-gene targeting.

Authors:  Martin Hart; Fabian Kern; Christina Backes; Stefanie Rheinheimer; Tobias Fehlmann; Andreas Keller; Eckart Meese
Journal:  RNA Biol       Date:  2018-05-11       Impact factor: 4.652

7.  Inverse correlation of expression of microRNA-140-5p with progression of multiple sclerosis and differentiation of encephalitogenic T helper type 1 cells.

Authors:  Hongbing Guan; Udai P Singh; Roshni Rao; Davit Mrelashvili; Souvik Sen; Haiping Hao; Elizabeth E Zumbrun; Narendra P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Immunology       Date:  2016-02-17       Impact factor: 7.397

8.  Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients.

Authors:  L C M Arruda; J C C Lorenzi; A P A Sousa; D L Zanette; P V B Palma; R A Panepucci; D S Brum; A A Barreira; D T Covas; B P Simões; W A Silva; M C Oliveira; K C R Malmegrim
Journal:  Bone Marrow Transplant       Date:  2014-12-08       Impact factor: 5.483

9.  Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.

Authors:  William J Magner; Bianca Weinstock-Guttman; Mina Rho; David Hojnacki; Rabia Ghazi; Murali Ramanathan; Thomas B Tomasi
Journal:  J Neuroimmunol       Date:  2016-01-21       Impact factor: 3.478

10.  Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.

Authors:  Petra Leidinger; Martin Hart; Christina Backes; Stefanie Rheinheimer; Bastian Keck; Bernd Wullich; Andreas Keller; Eckart Meese
Journal:  Tumour Biol       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.